TY - JOUR AU - Bersanelli, M. AU - Minari, R. AU - Bordi, P. PY - 2016 DA - 2016// TI - L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.05.019 DO - 10.1016/j.jtho.2016.05.019 ID - Bersanelli2016 ER - TY - JOUR AU - Rami-Porta, R. PY - 2015 DA - 2015// TI - The IASLC lung Cancer staging project JO - J Thoracic Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000559 DO - 10.1097/JTO.0000000000000559 ID - Rami-Porta2015 ER - TY - JOUR AU - Gong, L. AU - Xiong, M. AU - Huang, Z. PY - 2015 DA - 2015// TI - Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations JO - Lung Cancer VL - 89 UR - https://doi.org/10.1016/j.lungcan.2015.06.001 DO - 10.1016/j.lungcan.2015.06.001 ID - Gong2015 ER - TY - JOUR AU - Kawamura, T. AU - Hata, A. AU - Takeshita, J. PY - 2015 DA - 2015// TI - High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs JO - Cancer Chemother Pharmacol VL - 75 UR - https://doi.org/10.1007/s00280-015-2759-y DO - 10.1007/s00280-015-2759-y ID - Kawamura2015 ER - TY - JOUR AU - Zhu, W. AU - Zhou, L. AU - Qian, J. Q. PY - 2014 DA - 2014// TI - Temozolomide for treatment of brain metastases: a review of 21 clinical trials JO - World J Clin Oncol VL - 5 UR - https://doi.org/10.5306/wjco.v5.i1.19 DO - 10.5306/wjco.v5.i1.19 ID - Zhu2014 ER - TY - JOUR AU - Morichika, D. AU - Kubo, T. AU - Gotoda, H. PY - 2016 DA - 2016// TI - Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation JO - Onco Targets Ther VL - 9 ID - Morichika2016 ER - TY - JOUR AU - Langerijt, B. AU - Gijtenbeek, J. M. AU - Reus, H. P. PY - 2006 DA - 2006// TI - CSF levels of growth factors and plasminogen activators in leptomeningeal metastases JO - Neurology. VL - 67 UR - https://doi.org/10.1212/01.wnl.0000223348.42106.97 DO - 10.1212/01.wnl.0000223348.42106.97 ID - Langerijt2006 ER - TY - JOUR AU - Jiang, L. AU - Li, P. AU - Gong, Z. PY - 2016 DA - 2016// TI - Effective treatment for malignant pleural effusion and ascites with combined therapy of bevacizumab and cisplatin JO - Anticancer Res VL - 3 ID - Jiang2016 ER - TY - JOUR AU - Thress, K. S. AU - Paweletz, C. P. AU - Felip, E. PY - 2015 DA - 2015// TI - Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M JO - Nat Med VL - 21 UR - https://doi.org/10.1038/nm.3854 DO - 10.1038/nm.3854 ID - Thress2015 ER - TY - JOUR AU - Lee, J. AU - Shim, J. H. AU - Park, W. Y. PY - 2019 DA - 2019// TI - Rare mechanism of acquired resistance to osimertinib in Korean patients with EGFR-mutated non-small cell lung cancer JO - Cancer Res Treat VL - 51 UR - https://doi.org/10.4143/crt.2018.138 DO - 10.4143/crt.2018.138 ID - Lee2019 ER - TY - JOUR AU - Yang, Z. AU - Yang, N. AU - Ou, Q. PY - 2018 DA - 2018// TI - Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients JO - Clin Cancer Res VL - 24 UR - https://doi.org/10.1158/1078-0432.CCR-17-2310 DO - 10.1158/1078-0432.CCR-17-2310 ID - Yang2018 ER - TY - JOUR AU - Callegari, D. AU - Ranaghan, K. E. AU - Woods, C. J. PY - 2018 DA - 2018// TI - L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung ca ncer drug osimertinib JO - Chem Sci VL - 9 UR - https://doi.org/10.1039/C7SC04761D DO - 10.1039/C7SC04761D ID - Callegari2018 ER - TY - JOUR AU - Ercan, D. AU - Choi, H. G. AU - Yun, C. H. PY - 2015 DA - 2015// TI - EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-2789 DO - 10.1158/1078-0432.CCR-14-2789 ID - Ercan2015 ER - TY - JOUR AU - Ho, C. C. AU - Liao, W. Y. AU - Lin, C. A. PY - 2017 DA - 2017// TI - Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2016.11.2231 DO - 10.1016/j.jtho.2016.11.2231 ID - Ho2017 ER -